NO319030B1 - Paroxetinmetansulfonat, anvendelse derav samt fremgangsmate for fremstilling og farmasoytisk preparat. - Google Patents

Paroxetinmetansulfonat, anvendelse derav samt fremgangsmate for fremstilling og farmasoytisk preparat. Download PDF

Info

Publication number: NO319030B1
Authority: NO; Norway
Prior art keywords: paroxetine; solution; crystallization; solvent; paroxetine methanesulfonate
Prior art date: 1998-07-02

Application number

NO19991944A

Other languages

English (en)

Norwegian (no)

Other versions

NO991944L (no

NO991944D0 (no

Inventor

Neal Ward

Alan David Jones

Deirdre O'keefe

Andrew Simon Craig

Original Assignee

Smithkline Beecham Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-07-02

Filing date

1999-04-23

Publication date

2005-06-06

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27269380&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO319030(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1998-07-02 Priority claimed from GBGB9814316.7A external-priority patent/GB9814316D0/en

1998-10-06 Priority claimed from GBGB9821732.6A external-priority patent/GB9821732D0/en

1999-02-10 Priority claimed from GBGB9902935.7A external-priority patent/GB9902935D0/en

1999-04-23 Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc

1999-04-23 Publication of NO991944D0 publication Critical patent/NO991944D0/no

2000-01-03 Publication of NO991944L publication Critical patent/NO991944L/no

2005-06-06 Publication of NO319030B1 publication Critical patent/NO319030B1/no

Links

SHIJTGJXUHTGGZ-RVXRQPKJSA-N (3s,4r)-3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidin-1-ium;methanesulfonate Chemical compound CS(O)(=O)=O.C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 SHIJTGJXUHTGGZ-RVXRQPKJSA-N 0.000 title claims description 151
238000000034 method Methods 0.000 title claims description 35
238000002360 preparation method Methods 0.000 title claims description 27
239000000825 pharmaceutical preparation Substances 0.000 title claims description 7
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 162
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 109
238000002425 crystallisation Methods 0.000 claims description 84
230000008025 crystallization Effects 0.000 claims description 83
239000002904 solvent Substances 0.000 claims description 79
239000000203 mixture Substances 0.000 claims description 68
229940098779 methanesulfonic acid Drugs 0.000 claims description 52
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 45
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 38
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 35
150000003839 salts Chemical class 0.000 claims description 27
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 21
-1 amine salt Chemical class 0.000 claims description 19
238000001816 cooling Methods 0.000 claims description 12
239000012458 free base Substances 0.000 claims description 12
238000001953 recrystallisation Methods 0.000 claims description 11
150000001875 compounds Chemical class 0.000 claims description 10
150000002148 esters Chemical class 0.000 claims description 10
239000012296 anti-solvent Substances 0.000 claims description 8
150000002576 ketones Chemical class 0.000 claims description 8
239000000126 substance Substances 0.000 claims description 8
239000003086 colorant Substances 0.000 claims description 7
230000008569 process Effects 0.000 claims description 7
150000008282 halocarbons Chemical class 0.000 claims description 5
150000002825 nitriles Chemical class 0.000 claims description 4
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 3
208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 3
238000010533 azeotropic distillation Methods 0.000 claims description 3
239000011230 binding agent Substances 0.000 claims description 3
239000003755 preservative agent Substances 0.000 claims description 3
230000002335 preservative effect Effects 0.000 claims description 3
230000002265 prevention Effects 0.000 claims description 3
239000002775 capsule Substances 0.000 claims description 2
229940079593 drug Drugs 0.000 claims description 2
239000003814 drug Substances 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
238000002955 isolation Methods 0.000 claims description 2
208000019906 panic disease Diseases 0.000 claims description 2
206010036618 Premenstrual syndrome Diseases 0.000 claims 2
208000007848 Alcoholism Diseases 0.000 claims 1
208000024827 Alzheimer disease Diseases 0.000 claims 1
208000019901 Anxiety disease Diseases 0.000 claims 1
208000032841 Bulimia Diseases 0.000 claims 1
206010006550 Bulimia nervosa Diseases 0.000 claims 1
208000000094 Chronic Pain Diseases 0.000 claims 1
208000020401 Depressive disease Diseases 0.000 claims 1
208000019695 Migraine disease Diseases 0.000 claims 1
208000008589 Obesity Diseases 0.000 claims 1
208000002193 Pain Diseases 0.000 claims 1
206010039966 Senile dementia Diseases 0.000 claims 1
206010041250 Social phobia Diseases 0.000 claims 1
201000007930 alcohol dependence Diseases 0.000 claims 1
208000022531 anorexia Diseases 0.000 claims 1
230000036506 anxiety Effects 0.000 claims 1
206010061428 decreased appetite Diseases 0.000 claims 1
208000024732 dysthymic disease Diseases 0.000 claims 1
125000001033 ether group Chemical group 0.000 claims 1
206010027599 migraine Diseases 0.000 claims 1
208000015238 neurotic disease Diseases 0.000 claims 1
235000020824 obesity Nutrition 0.000 claims 1
201000009032 substance abuse Diseases 0.000 claims 1
231100000736 substance abuse Toxicity 0.000 claims 1
208000011117 substance-related disease Diseases 0.000 claims 1
208000002271 trichotillomania Diseases 0.000 claims 1
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 87
229960002296 paroxetine Drugs 0.000 description 81
AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 79
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 78
AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 76
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 51
238000001914 filtration Methods 0.000 description 49
239000002585 base Substances 0.000 description 45
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 39
239000000047 product Substances 0.000 description 35
239000007787 solid Substances 0.000 description 35
YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 29
DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 29
239000002244 precipitate Substances 0.000 description 26
238000010992 reflux Methods 0.000 description 25
238000003756 stirring Methods 0.000 description 25
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
239000006071 cream Substances 0.000 description 20
ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 19
238000001704 evaporation Methods 0.000 description 18
239000012453 solvate Substances 0.000 description 17
230000008020 evaporation Effects 0.000 description 16
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
238000006243 chemical reaction Methods 0.000 description 13
239000000843 powder Substances 0.000 description 13
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 12
239000002253 acid Substances 0.000 description 12
239000013078 crystal Substances 0.000 description 12
239000012297 crystallization seed Substances 0.000 description 12
230000007062 hydrolysis Effects 0.000 description 12
238000006460 hydrolysis reaction Methods 0.000 description 12
238000004519 manufacturing process Methods 0.000 description 12
238000001035 drying Methods 0.000 description 11
238000002329 infrared spectrum Methods 0.000 description 11
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
238000004090 dissolution Methods 0.000 description 9
150000002170 ethers Chemical class 0.000 description 9
238000002844 melting Methods 0.000 description 9
230000008018 melting Effects 0.000 description 9
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
150000001298 alcohols Chemical class 0.000 description 8
239000000725 suspension Substances 0.000 description 8
230000015572 biosynthetic process Effects 0.000 description 7
239000002245 particle Substances 0.000 description 7
230000001105 regulatory effect Effects 0.000 description 7
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
239000012298 atmosphere Substances 0.000 description 6
YKGMKSIHIVVYKY-UHFFFAOYSA-N dabrafenib mesylate Chemical compound CS(O)(=O)=O.S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 YKGMKSIHIVVYKY-UHFFFAOYSA-N 0.000 description 6
238000010438 heat treatment Methods 0.000 description 6
239000012299 nitrogen atmosphere Substances 0.000 description 6
238000001556 precipitation Methods 0.000 description 6
238000005481 NMR spectroscopy Methods 0.000 description 5
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
239000000463 material Substances 0.000 description 5
229910052757 nitrogen Inorganic materials 0.000 description 5
239000003921 oil Substances 0.000 description 5
238000000634 powder X-ray diffraction Methods 0.000 description 5
239000002243 precursor Substances 0.000 description 5
239000011541 reaction mixture Substances 0.000 description 5
238000000527 sonication Methods 0.000 description 5
239000007858 starting material Substances 0.000 description 5
239000002966 varnish Substances 0.000 description 5
QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 4
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
DHUXGFHEJUYKNX-UHFFFAOYSA-N acetonitrile;methanesulfonic acid Chemical compound CC#N.CS(O)(=O)=O DHUXGFHEJUYKNX-UHFFFAOYSA-N 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
150000004996 alkyl benzenes Chemical class 0.000 description 4
125000004093 cyano group Chemical group *C#N 0.000 description 4
RBLGLDWTCZMLRW-UHFFFAOYSA-K dicalcium;phosphate;dihydrate Chemical compound O.O.[Ca+2].[Ca+2].[O-]P([O-])([O-])=O RBLGLDWTCZMLRW-UHFFFAOYSA-K 0.000 description 4
238000009826 distribution Methods 0.000 description 4
229910052736 halogen Inorganic materials 0.000 description 4
150000002367 halogens Chemical class 0.000 description 4
239000007788 liquid Substances 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 4
125000006239 protecting group Chemical group 0.000 description 4
229920005989 resin Polymers 0.000 description 4
239000011347 resin Substances 0.000 description 4
239000011877 solvent mixture Substances 0.000 description 4
239000012258 stirred mixture Substances 0.000 description 4
MTJGVAJYTOXFJH-UHFFFAOYSA-N 3-aminonaphthalene-1,5-disulfonic acid Chemical compound C1=CC=C(S(O)(=O)=O)C2=CC(N)=CC(S(O)(=O)=O)=C21 MTJGVAJYTOXFJH-UHFFFAOYSA-N 0.000 description 3
150000001335 aliphatic alkanes Chemical class 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
239000012300 argon atmosphere Substances 0.000 description 3
150000004945 aromatic hydrocarbons Chemical class 0.000 description 3
238000005102 attenuated total reflection Methods 0.000 description 3
239000003054 catalyst Substances 0.000 description 3
125000004122 cyclic group Chemical group 0.000 description 3
238000010511 deprotection reaction Methods 0.000 description 3
239000012065 filter cake Substances 0.000 description 3
238000004108 freeze drying Methods 0.000 description 3
238000002156 mixing Methods 0.000 description 3
AEIUZSKXSWGSRU-QXGDPHCHSA-N paroxetine maleate Chemical group OC(=O)\C=C/C(O)=O.C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AEIUZSKXSWGSRU-QXGDPHCHSA-N 0.000 description 3
238000002604 ultrasonography Methods 0.000 description 3
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
238000013019 agitation Methods 0.000 description 2
150000005215 alkyl ethers Chemical class 0.000 description 2
125000000217 alkyl group Chemical group 0.000 description 2
150000001408 amides Chemical class 0.000 description 2
239000000935 antidepressant agent Substances 0.000 description 2
229940005513 antidepressants Drugs 0.000 description 2
239000006286 aqueous extract Substances 0.000 description 2
239000008346 aqueous phase Substances 0.000 description 2
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
238000009835 boiling Methods 0.000 description 2
150000001735 carboxylic acids Chemical class 0.000 description 2
238000004040 coloring Methods 0.000 description 2
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
239000000975 dye Substances 0.000 description 2
238000010828 elution Methods 0.000 description 2
239000012156 elution solvent Substances 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
238000005984 hydrogenation reaction Methods 0.000 description 2
239000012535 impurity Substances 0.000 description 2
238000011065 in-situ storage Methods 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
229910052943 magnesium sulfate Inorganic materials 0.000 description 2
235000019341 magnesium sulphate Nutrition 0.000 description 2
GTCAXTIRRLKXRU-UHFFFAOYSA-N methyl carbamate Chemical compound COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 description 2
239000012074 organic phase Substances 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
229960005183 paroxetine hydrochloride Drugs 0.000 description 2
XHNUMAXRQGMHKZ-CVDCTZTESA-N phenyl (3s,4r)-3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine-1-carboxylate Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CN(C(=O)OC=2C=CC=CC=2)CC1 XHNUMAXRQGMHKZ-CVDCTZTESA-N 0.000 description 2
BSCCSDNZEIHXOK-UHFFFAOYSA-N phenyl carbamate Chemical compound NC(=O)OC1=CC=CC=C1 BSCCSDNZEIHXOK-UHFFFAOYSA-N 0.000 description 2
PWXJULSLLONQHY-UHFFFAOYSA-N phenylcarbamic acid Chemical class OC(=O)NC1=CC=CC=C1 PWXJULSLLONQHY-UHFFFAOYSA-N 0.000 description 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
239000000376 reactant Substances 0.000 description 2
238000001374 small-angle light scattering Methods 0.000 description 2
229940079832 sodium starch glycolate Drugs 0.000 description 2
229920003109 sodium starch glycolate Polymers 0.000 description 2
239000008109 sodium starch glycolate Substances 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
238000001694 spray drying Methods 0.000 description 2
CLVFCWOLZUJZNI-YOEHRIQHSA-N (3s,4r)-3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine-1-carboxylic acid Chemical compound C1([C@@H]2CCN(C[C@H]2COC=2C=C3OCOC3=CC=2)C(=O)O)=CC=C(F)C=C1 CLVFCWOLZUJZNI-YOEHRIQHSA-N 0.000 description 1
125000006527 (C1-C5) alkyl group Chemical group 0.000 description 1
PYHRZPFZZDCOPH-QXGOIDDHSA-N (S)-amphetamine sulfate Chemical compound [H+].[H+].[O-]S([O-])(=O)=O.C[C@H](N)CC1=CC=CC=C1.C[C@H](N)CC1=CC=CC=C1 PYHRZPFZZDCOPH-QXGOIDDHSA-N 0.000 description 1
DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 1
238000005160 1H NMR spectroscopy Methods 0.000 description 1
QPLJYAKLSCXZSF-UHFFFAOYSA-N 2,2,2-trichloroethyl carbamate Chemical compound NC(=O)OCC(Cl)(Cl)Cl QPLJYAKLSCXZSF-UHFFFAOYSA-N 0.000 description 1
OWUUCBHKSSXUEJ-UHFFFAOYSA-N 2,4-dimethylpentan-3-yl carbamate Chemical compound CC(C)C(C(C)C)OC(N)=O OWUUCBHKSSXUEJ-UHFFFAOYSA-N 0.000 description 1
JMEVHYCNAPFOAB-UHFFFAOYSA-N 2-(3-hydroxy-5-sulfo-1H-indol-2-yl)-3-oxoindole-5-sulfonic acid Chemical compound Oc1c([nH]c2ccc(cc12)S(O)(=O)=O)C1=Nc2ccc(cc2C1=O)S(O)(=O)=O JMEVHYCNAPFOAB-UHFFFAOYSA-N 0.000 description 1
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
229920003084 Avicel® PH-102 Polymers 0.000 description 1
DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
MXRIRQGCELJRSN-UHFFFAOYSA-N O.O.O.[Al] Chemical compound O.O.O.[Al] MXRIRQGCELJRSN-UHFFFAOYSA-N 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
229910001069 Ti alloy Inorganic materials 0.000 description 1
XAKBSHICSHRJCL-UHFFFAOYSA-N [CH2]C(=O)C1=CC=CC=C1 Chemical group [CH2]C(=O)C1=CC=CC=C1 XAKBSHICSHRJCL-UHFFFAOYSA-N 0.000 description 1
DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
150000001241 acetals Chemical class 0.000 description 1
150000003869 acetamides Chemical class 0.000 description 1
KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
RQBJOWKBGCDPOS-RVXRQPKJSA-N acetic acid;(3s,4r)-3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine Chemical compound CC(O)=O.C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 RQBJOWKBGCDPOS-RVXRQPKJSA-N 0.000 description 1
125000002339 acetoacetyl group Chemical group O=C([*])C([H])([H])C(=O)C([H])([H])[H] 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
150000008044 alkali metal hydroxides Chemical class 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
125000002877 alkyl aryl group Chemical group 0.000 description 1
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
230000001430 anti-depressive effect Effects 0.000 description 1
230000000648 anti-parkinson Effects 0.000 description 1
239000000939 antiparkinson agent Substances 0.000 description 1
244000052616 bacterial pathogen Species 0.000 description 1
230000008901 benefit Effects 0.000 description 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
PUJDIJCNWFYVJX-UHFFFAOYSA-N benzyl carbamate Chemical compound NC(=O)OCC1=CC=CC=C1 PUJDIJCNWFYVJX-UHFFFAOYSA-N 0.000 description 1
239000008609 bushi Substances 0.000 description 1
150000004657 carbamic acid derivatives Chemical class 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
239000000969 carrier Substances 0.000 description 1
229920001429 chelating resin Polymers 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
239000006184 cosolvent Substances 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
150000004292 cyclic ethers Chemical class 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000004821 distillation Methods 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
239000011521 glass Substances 0.000 description 1
239000003365 glass fiber Substances 0.000 description 1
FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000004179 indigotine Substances 0.000 description 1
235000012738 indigotine Nutrition 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
229940011051 isopropyl acetate Drugs 0.000 description 1
GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
239000004922 lacquer Substances 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000000155 melt Substances 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical group CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
229940043265 methyl isobutyl ketone Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
239000012046 mixed solvent Substances 0.000 description 1
YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 description 1
150000002832 nitroso derivatives Chemical class 0.000 description 1
230000006911 nucleation Effects 0.000 description 1
238000010899 nucleation Methods 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
238000000643 oven drying Methods 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
229910001392 phosphorus oxide Inorganic materials 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
OCAAZRFBJBEVPS-UHFFFAOYSA-N prop-2-enyl carbamate Chemical compound NC(=O)OCC=C OCAAZRFBJBEVPS-UHFFFAOYSA-N 0.000 description 1
XYKIUTSFQGXHOW-UHFFFAOYSA-N propan-2-one;toluene Chemical compound CC(C)=O.CC1=CC=CC=C1 XYKIUTSFQGXHOW-UHFFFAOYSA-N 0.000 description 1
229940090181 propyl acetate Drugs 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
125000001453 quaternary ammonium group Chemical group 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
238000000926 separation method Methods 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
238000007711 solidification Methods 0.000 description 1
230000008023 solidification Effects 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000000758 substrate Substances 0.000 description 1
238000001308 synthesis method Methods 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000009492 tablet coating Methods 0.000 description 1
239000002700 tablet coating Substances 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
WGHIJTFVCGNFTJ-UHFFFAOYSA-N tert-butyl 2-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine-1-carboxylate Chemical compound C1C(COC=2C=C3OCOC3=CC=2)N(C(=O)OC(C)(C)C)CCC1C1=CC=C(F)C=C1 WGHIJTFVCGNFTJ-UHFFFAOYSA-N 0.000 description 1
125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
VSAISIQCTGDGPU-UHFFFAOYSA-N tetraphosphorus hexaoxide Chemical compound O1P(O2)OP3OP1OP2O3 VSAISIQCTGDGPU-UHFFFAOYSA-N 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
238000001291 vacuum drying Methods 0.000 description 1
238000003828 vacuum filtration Methods 0.000 description 1
NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
LVLANIHJQRZTPY-UHFFFAOYSA-N vinyl carbamate Chemical compound NC(=O)OC=C LVLANIHJQRZTPY-UHFFFAOYSA-N 0.000 description 1
238000005406 washing Methods 0.000 description 1
239000008096 xylene Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Inorganic Chemistry (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Psychology (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Hematology (AREA)
Addiction (AREA)
Child & Adolescent Psychology (AREA)
Obesity (AREA)
Plural Heterocyclic Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Hydrogenated Pyridines (AREA)
Medicinal Preparation (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

NO19991944A 1998-07-02 1999-04-23 Paroxetinmetansulfonat, anvendelse derav samt fremgangsmate for fremstilling og farmasoytisk preparat. NO319030B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB9814316.7A GB9814316D0 (en)	1998-07-02	1998-07-02	Novel compounds
GBGB9821732.6A GB9821732D0 (en)	1998-10-06	1998-10-06	Novel compound
GBGB9902935.7A GB9902935D0 (en)	1999-02-10	1999-02-10	Novel compound

Publications (3)

Publication Number	Publication Date
NO991944D0 NO991944D0 (no)	1999-04-23
NO991944L NO991944L (no)	2000-01-03
NO319030B1 true NO319030B1 (no)	2005-06-06

Family

ID=27269380

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19991944A NO319030B1 (no)	1998-07-02	1999-04-23	Paroxetinmetansulfonat, anvendelse derav samt fremgangsmate for fremstilling og farmasoytisk preparat.

Country Status (35)

Country	Link
US (4)	US6063927A (fi)
EP (5)	EP1020464B1 (fi)
JP (1)	JP2002519422A (fi)
KR (1)	KR20010053336A (fi)
CN (1)	CN1127502C (fi)
AR (2)	AR011759A1 (fi)
AT (4)	ATE251155T1 (fi)
AU (4)	AU3619199A (fi)
BE (3)	BE1012403A5 (fi)
BR (1)	BR9911682A (fi)
CA (1)	CA2269999A1 (fi)
CH (1)	CH689805A8 (fi)
DE (5)	DE19918588A1 (fi)
DK (7)	DK199900176U3 (fi)
ES (4)	ES2158778B1 (fi)
FI (2)	FI112077B (fi)
FR (2)	FR2780728B1 (fi)
GB (5)	GB2336364B (fi)
GR (3)	GR990100140A (fi)
HK (1)	HK1037877A1 (fi)
HU (1)	HUP0102334A3 (fi)
IE (5)	IE990344A1 (fi)
IL (1)	IL140628A (fi)
IT (1)	IT1312540B1 (fi)
LU (1)	LU90388B1 (fi)
NL (4)	NL1011875C2 (fi)
NO (1)	NO319030B1 (fi)
NZ (1)	NZ509180A (fi)
PL (1)	PL345214A1 (fi)
PT (4)	PT1089996E (fi)
SE (1)	SE9901462A0 (fi)
SI (3)	SI1020464T1 (fi)
SK (1)	SK20262000A3 (fi)
TR (1)	TR200100054T2 (fi)
WO (1)	WO2000001694A1 (fi)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5998401A (en) *	1995-02-28	1999-12-07	Eli Lilly And Company	Naphthyl compounds, intermediates, compositions, and methods
JP4081820B2 (ja) *	1997-02-27	2008-04-30	味の素株式会社	晶析装置及び晶析方法
ATE200781T1 (de) *	1997-06-10	2001-05-15	Synthon Bv	4-phenylpiperidin-derivate
CH689805A8 (fr) *	1998-07-02	2000-02-29	Smithkline Beecham Plc	Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
US20040028582A1 (en) *	1999-03-10	2004-02-12	Smithkline Beecham Corporation	Crystallization process for producing fine crystal products
USPP12225P2 (en)	1999-06-01	2001-11-27	Florfis Ag	Geranium plant named ‘Fislamda’
ES2159260B1 (es) *	1999-06-22	2002-05-01	Smithkline Beechan Plc	Nueva composicion de metanosulfonato de paroxetina
WO2000078290A2 (en) *	1999-06-22	2000-12-28	Smithkline Beecham P.L.C.	Pharmaceutical composition comprising a salt of paroxetine
GB0003232D0 (en) *	2000-02-11	2000-04-05	Smithkline Beecham Plc	Novel composition
US6306435B1 (en)	2000-06-26	2001-10-23	Yung Shin Pharmaceutical Industrial Co. Ltd.	Oral pharmaceutical preparation embedded in an oily matrix and methods of making the same
GB0015981D0 (en) *	2000-06-29	2000-08-23	Glaxo Group Ltd	Novel process for preparing crystalline particles
NZ523902A (en) *	2000-08-28	2004-05-28	Synthon Bv	Paroxetine compositions and processes for making the same
DE20100529U1 (de) *	2001-01-11	2001-05-10	Synthon Bv	Pharmazeutische Tablette umfassend Paroxetinmesylat
NL1017421C2 (nl) *	2001-02-21	2002-01-15	Synthon Bv	Werkwijze voor het vervaardigen van paroxetine.
EP1412350A1 (en) *	2001-08-02	2004-04-28	Spurcourt Limited	Paroxetine isethionate salt, process of preparation and use in the treatment of depression
JP4625637B2 (ja)	2002-02-22	2011-02-02	シャイアエルエルシー	活性物質送達系及び活性物質を保護し投与する方法
US20050266082A1 (en) *	2004-05-26	2005-12-01	Patel Satishkumar A	Preparation of stable paroxetine HC1 ER tablets using a melt granulation process
US20060063737A1 (en) *	2004-08-18	2006-03-23	Holmdahl Lisa K	Liquid paroxetine compositions
WO2006023347A1 (en) *	2004-08-20	2006-03-02	Alpharma, Inc.	Paroxetine formulations
KR100672184B1 (ko)	2004-09-21	2007-01-19	주식회사종근당	파록세틴의 콜린산 또는 콜린산 유도체 염
WO2006110553A2 (en) *	2005-04-07	2006-10-19	Xy, Inc.	Flow path conditioner system
AU2006315684A1 (en) *	2005-11-14	2007-05-24	Auspex Pharmaceuticals, Inc.	Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
US8722884B2 (en) *	2005-12-01	2014-05-13	Verastem, Inc.	Pyrimidine derivatives for the treatment of abnormal cell growth
US20080033050A1 (en)	2006-08-04	2008-02-07	Richards Patricia Allison Tewe	Method of treating thermoregulatory disfunction with paroxetine
JP2010520879A (ja) *	2007-03-09	2010-06-17	ノバルティスアーゲー	３−（１ｈ−インドール−３−イル）−４−［２−（４−メチル−ピペラジン−１−イル）−キナゾリン−４−イル］−ピロール−２，５−ジオンの塩
US8119688B2 (en) *	2007-09-19	2012-02-21	Xy, Llc	Differential evaporation potentiated disinfectant system
US20100249166A1 (en) *	2007-09-19	2010-09-30	Xy, Inc.	Differential evaporation potentiated disinfectant system
FR2926552B1 (fr) *	2008-01-23	2010-03-26	Biocodex	Procede de preparation de particules de stiripentol ayant une granulometrie definie
CN103961333B (zh) *	2014-05-07	2020-02-21	浙江华海药业股份有限公司	甲磺酸帕罗西汀胶囊及其制备方法
CN104523645A (zh) *	2014-11-20	2015-04-22	美吉斯制药（厦门）有限公司	甲磺酸帕罗西汀片芯及其包衣片的制备方法
US11111373B2 (en)	2018-12-05	2021-09-07	Chi Mei Corporation	Polymethacrylate composition and optical device made therefrom, and display apparatus

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE99678C (fi) *
GB1422263A (en) *	1973-01-30	1976-01-21	Ferrosan As	4-phenyl-piperidine compounds
US4585777A (en) *	1984-02-07	1986-04-29	A/S Ferrosan	(-)-Trans-4-(4-fluorophenyl)-3-(4-methoxyphenoxy)methylpiperidine for potentiating 5-HT
GB8430581D0 (en) *	1984-12-04	1985-01-09	Ferrosan As	Treatment
EP0190496A3 (en) *	1984-12-13	1987-05-27	Beecham Group Plc	Piperidine derivatives having a gastro-intestinal activity
GB8520154D0 (en) *	1985-08-10	1985-09-18	Beecham Group Plc	Chemical process
EP0223334B1 (en) *	1985-08-10	1991-07-10	Beecham Group Plc	Process for the preparation of aryl-piperidine carbinols
DE3677712D1 (de) *	1985-10-21	1991-04-04	Honda Motor Co Ltd	Methode zur steuerung des spulenstroms eines magnetventils, das die saufluftmenge eines innenverbrennungsmotors steuert.
DE3688827T2 (de) *	1985-10-25	1994-03-31	Beecham Group Plc	Piperidinderivat, seine Herstellung und seine Verwendung als Arzneimittel.
IE66332B1 (en) *	1986-11-03	1995-12-27	Novo Nordisk As	Piperidine compounds and their preparation and use
GB8626936D0 (en) *	1986-11-11	1986-12-10	Ferrosan As	Treatment
JPS63141967A (ja) *	1986-11-21	1988-06-14	エイ・エッチ・ロビンス・カンパニー・インコーポレーテッド	抗アレルギー薬として有用な１−アリールオキシー４−［（４−アリール）−１−ピペラジニル］−２−ブタノール
GB8714707D0 (en) *	1987-06-23	1987-07-29	Beecham Group Plc	Chemical process
DK715988D0 (da) *	1988-12-22	1988-12-22	Ferrosan As	Etherifikation og dealkylering af piperidin-derivater samt intermediater
DK716088D0 (da) *	1988-12-22	1988-12-22	Ferrosan As	Reduktion af piperidin-dion-derivater samt intermediat
EP0558679A1 (en) *	1990-11-24	1993-09-08	BEECHAM GROUP plc	Use of paroxetine for the treatment of senile dementia, bulimia, migraine or anorexia
GB9209687D0 (en) *	1992-05-06	1992-06-17	Smithkline Beecham Plc	Novel process
US5258517A (en) *	1992-08-06	1993-11-02	Sepracor, Inc.	Method of preparing optically pure precursors of paroxetine
JP2773587B2 (ja) *	1992-11-30	1998-07-09	東レ株式会社	Ｏ，ｏ´−ジアシル酒石酸無水物の製造法
US5276042A (en) *	1993-04-16	1994-01-04	Crenshaw Roger T	Treatment of premature ejaculation
US5546683A (en) *	1993-09-29	1996-08-20	Clark; George J.	Bucket attachment device with remote controlled retractable pins
IT1274241B (it) *	1993-12-03	1997-07-15	Smithkline Beecham Farma	Complessi agente terapeutico/matrice polimerica dotati di migliorate caratteristiche di sapore e composizioni farmaceutiche che li contengono
GB9325644D0 (en) *	1993-12-15	1994-02-16	Smithkline Beecham Plc	Novel formulation
US5668134A (en) *	1994-01-28	1997-09-16	G. D. Searle & Co.	Method for preventing or reducing photosensitivity and/or phototoxicity reactions to medications
GB9402029D0 (en) *	1994-02-03	1994-03-30	Smithkline Beecham Plc	Novel formulation
CA2143070C (en) *	1994-02-22	2001-12-18	Pankaj Modi	Oral controlled release liquid suspension pharmaceutical formulation
EP0714663A3 (en) *	1994-11-28	1997-01-15	Lilly Co Eli	Potentiation of drug responses by serotonin 1A receptor antagonists
GB2297550B (en) *	1995-02-06	1997-04-09	Smithkline Beecham Plc	Paroxetine hydrochloride anhydrate substantially free of bound organic solvent
AR001982A1 (es) *	1995-02-06	1998-01-07	Smithkline Beecham Plc	Clorhidrato de paroxetina anhidratado, y procedimiento para su preparacion
JP3768536B2 (ja) *	1995-04-03	2006-04-19	アボツト・ラボラトリーズ	低温溶融性薬物と制御放出のための添加物との均質混合物
NZ307479A (en) *	1995-05-17	1999-08-30	Novo Nordisk As	A process for preparing 4-(4-halo substituted phenyl)-3-(3,4-methylenedioxy phenoxy methyl)piperidine derivatives
JP2813768B2 (ja) *	1995-05-24	1998-10-22	農林水産省家畜衛生試験場長	口蹄疫診断用ペプチドおよび当該ペプチドを含有する口蹄疫診断用抗原
GB9514842D0 (en) *	1995-07-20	1995-09-20	Smithkline Beecham Plc	Novel formulation
JP3081250B2 (ja) *	1995-10-31	2000-08-28	メルクエンドカンパニーインコーポレーテッド	置換アゼチジノンの製造方法
IT1276160B1 (it) *	1995-11-22	1997-10-27	Recordati Chem Pharm	Composizioni farmaceutiche orali a pronto rilascio per sospensioni estemporanee
GB9526645D0 (en) *	1995-12-28	1996-02-28	Chiroscience Ltd	Stereoselective synthesis
ES2117557B1 (es) *	1996-02-29	1999-07-01	Ferrer Int	Nuevo procedimiento de obtencion de (-)-trans -n-p-fluorobenzoilmetil-4-(p-fluorofenil)-3- ((3,4-(metilendioxi)fenoxi ) metil)-piperidina.
JP3446468B2 (ja) *	1996-04-15	2003-09-16	旭硝子株式会社	ピペリジンカルビノール類の製造方法
CA2206592A1 (en) *	1996-05-30	1997-11-30	Shu-Zhong Wang	Method of producing amorphous paroxetine hydrochloride
JP3882224B2 (ja) *	1996-05-31	2007-02-14	旭硝子株式会社	パロキセチンの製造方法
EP1384720A1 (en) *	1996-06-13	2004-01-28	SUMIKA FINE CHEMICALS Co., Ltd.	Process for drying paroxetine hydrochloride
HU221921B1 (hu) *	1996-07-08	2003-02-28	Richter Gedeon Vegyészeti Gyár Rt.	N-benzil-piperidin- és tetrahidropiridinszármazékok és eljárás azok előállítására
US5672609A (en) *	1996-07-18	1997-09-30	Eli Lilly And Company	Pyridine compounds, intermediates compositions and methods of use
CA2187128A1 (en) *	1996-10-04	1997-06-26	K. S. Keshava Murthy	New and useful polymorph of anhydrous paroxetine hydrochloride
ATE200781T1 (de) *	1997-06-10	2001-05-15	Synthon Bv	4-phenylpiperidin-derivate
KR20010040711A (ko) *	1998-02-06	2001-05-15	피터 기딩스	파록세틴의 염
EA200000946A1 (ru) *	1998-03-16	2001-02-26	Смитклайн Бичам Плс	Кристаллическая форма пароксетина
AP2000001950A0 (en) *	1998-04-09	2000-12-31	Smithkline Beecham Plc	Paroxetine maleate.
CH689805A8 (fr) *	1998-07-02	2000-02-29	Smithkline Beecham Plc	Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
ES2159260B1 (es) *	1999-06-22	2002-05-01	Smithkline Beechan Plc	Nueva composicion de metanosulfonato de paroxetina
DE20100529U1 (de) *	2001-01-11	2001-05-10	Synthon Bv	Pharmazeutische Tablette umfassend Paroxetinmesylat

1999
- 1999-04-20 CH CH00723/99A patent/CH689805A8/fr not_active IP Right Cessation
- 1999-04-23 EP EP00201290A patent/EP1020464B1/en not_active Revoked
- 1999-04-23 ES ES009900849A patent/ES2158778B1/es not_active Expired - Fee Related
- 1999-04-23 DK DK199900176U patent/DK199900176U3/da not_active IP Right Cessation
- 1999-04-23 GR GR990100140A patent/GR990100140A/el not_active IP Right Cessation
- 1999-04-23 AT AT99918159T patent/ATE251155T1/de not_active IP Right Cessation
- 1999-04-23 JP JP2000558097A patent/JP2002519422A/ja active Pending
- 1999-04-23 ES ES99303151T patent/ES2149044T3/es not_active Expired - Lifetime
- 1999-04-23 AU AU36191/99A patent/AU3619199A/en not_active Abandoned
- 1999-04-23 AU AU23928/99A patent/AU732211C/en not_active Ceased
- 1999-04-23 PT PT99918159T patent/PT1089996E/pt unknown
- 1999-04-23 GB GB9909505A patent/GB2336364B/en not_active Revoked
- 1999-04-23 AT AT0027999U patent/AT3185U3/de not_active IP Right Cessation
- 1999-04-23 NZ NZ509180A patent/NZ509180A/en unknown
- 1999-04-23 GB GB0216752A patent/GB2377637A/en not_active Withdrawn
- 1999-04-23 FR FR9905185A patent/FR2780728B1/fr not_active Expired - Fee Related
- 1999-04-23 IE IE19990344A patent/IE990344A1/en not_active IP Right Cessation
- 1999-04-23 ES ES99918159T patent/ES2209428T3/es not_active Expired - Lifetime
- 1999-04-23 EP EP00201289A patent/EP1020463A1/en not_active Withdrawn
- 1999-04-23 AU AU23937/99A patent/AU713131B3/en not_active Ceased
- 1999-04-23 BR BR9911682-0A patent/BR9911682A/pt not_active Application Discontinuation
- 1999-04-23 IE IE20000894A patent/IES20000894A2/en not_active Application Discontinuation
- 1999-04-23 DK DK99918159T patent/DK1089996T3/da active
- 1999-04-23 GB GB0026487A patent/GB2352395B/en not_active Expired - Fee Related
- 1999-04-23 DK DK199900554A patent/DK199900554A/da not_active Application Discontinuation
- 1999-04-23 WO PCT/GB1999/001253 patent/WO2000001694A1/en not_active Application Discontinuation
- 1999-04-23 AU AU23938/99A patent/AU713877B3/en not_active Ceased
- 1999-04-23 NL NL1011875A patent/NL1011875C2/nl not_active IP Right Cessation
- 1999-04-23 SI SI9930009T patent/SI1020464T1/xx unknown
- 1999-04-23 PT PT79901275T patent/PT1020464E/pt unknown
- 1999-04-23 EP EP99303151A patent/EP0970955B1/en not_active Revoked
- 1999-04-23 SK SK2026-2000A patent/SK20262000A3/sk unknown
- 1999-04-23 US US09/299,060 patent/US6063927A/en not_active Expired - Fee Related
- 1999-04-23 CA CA002269999A patent/CA2269999A1/en not_active Abandoned
- 1999-04-23 DE DE19918588A patent/DE19918588A1/de not_active Ceased
- 1999-04-23 IL IL14062899A patent/IL140628A/en not_active IP Right Cessation
- 1999-04-23 KR KR1020007015099A patent/KR20010053336A/ko not_active Application Discontinuation
- 1999-04-23 BE BE9900293A patent/BE1012403A5/fr not_active IP Right Cessation
- 1999-04-23 BE BE9900294A patent/BE1011664A6/fr not_active IP Right Cessation
- 1999-04-23 IE IE20000893A patent/IES20000893A2/en not_active IP Right Cessation
- 1999-04-23 SI SI9930482T patent/SI1089996T1/xx unknown
- 1999-04-23 FI FI990922A patent/FI112077B/fi active
- 1999-04-23 AT AT99303151T patent/ATE195121T1/de not_active IP Right Cessation
- 1999-04-23 CN CN99810281A patent/CN1127502C/zh not_active Expired - Fee Related
- 1999-04-23 PL PL99345214A patent/PL345214A1/xx not_active Application Discontinuation
- 1999-04-23 GB GB0119695A patent/GB2367003A/en not_active Withdrawn
- 1999-04-23 NO NO19991944A patent/NO319030B1/no unknown
- 1999-04-23 IE IE19990343 patent/IES81166B2/en not_active IP Right Cessation
- 1999-04-23 NL NL1011874A patent/NL1011874C1/nl not_active IP Right Cessation
- 1999-04-23 DE DE69900007T patent/DE69900007T2/de not_active Revoked
- 1999-04-23 EP EP02078483A patent/EP1288214A1/en not_active Withdrawn
- 1999-04-23 HU HU0102334A patent/HUP0102334A3/hu unknown
- 1999-04-23 DK DK99303151T patent/DK0970955T3/da active
- 1999-04-23 PT PT102291A patent/PT102291B/pt not_active IP Right Cessation
- 1999-04-23 EP EP99918159A patent/EP1089996B1/en not_active Expired - Lifetime
- 1999-04-23 GB GB9920332A patent/GB2339428A/en not_active Withdrawn
- 1999-04-23 IT IT1999MI000866A patent/IT1312540B1/it active
- 1999-04-23 DE DE69911774T patent/DE69911774T2/de not_active Expired - Fee Related
- 1999-04-23 LU LU90388A patent/LU90388B1/fr active
- 1999-04-23 IE IE20000633A patent/IE20000633A1/en not_active IP Right Cessation
- 1999-04-23 SE SE9901462A patent/SE9901462A0/sv not_active Application Discontinuation
- 1999-04-23 FI FI990190U patent/FI4209U1/fi not_active IP Right Cessation
- 1999-04-23 AR ARP990101885A patent/AR011759A1/es not_active Application Discontinuation
- 1999-04-23 PT PT99303151T patent/PT970955E/pt unknown
- 1999-04-23 DE DE29907248U patent/DE29907248U1/de not_active Expired - Lifetime
- 1999-04-23 SI SI9930002T patent/SI0970955T1/xx unknown
- 1999-04-23 TR TR2001/00054T patent/TR200100054T2/xx unknown
- 1999-04-26 AR ARP990101908A patent/AR018197A1/es unknown
- 1999-06-08 NL NL1012272A patent/NL1012272C1/nl not_active IP Right Cessation
- 1999-06-08 NL NL1012271A patent/NL1012271C2/nl not_active IP Right Cessation
- 1999-06-15 DK DK199900234U patent/DK199900234U4/da not_active IP Right Cessation
- 1999-12-23 BE BE9900832A patent/BE1012420A6/fr not_active IP Right Cessation
2000
- 2000-04-10 DE DE60000003T patent/DE60000003T2/de not_active Revoked
- 2000-04-10 AT AT00201290T patent/ATE202777T1/de not_active IP Right Cessation
- 2000-04-10 ES ES00201290T patent/ES2157881T3/es not_active Expired - Lifetime
- 2000-04-10 DK DK00201290T patent/DK1020464T3/da active
- 2000-09-05 GR GR20000402015T patent/GR3034328T3/el not_active IP Right Cessation
- 2000-11-08 FR FR0014325A patent/FR2802098A1/fr active Pending
- 2000-12-27 DK DK200000390U patent/DK200000390U1/da not_active IP Right Cessation
2001
- 2001-03-14 US US09/805,812 patent/US20010023253A1/en not_active Abandoned
- 2001-07-11 GR GR20010401061T patent/GR3036208T3/el not_active IP Right Cessation
- 2001-09-21 US US09/960,033 patent/US20020035130A1/en not_active Abandoned
- 2001-10-11 HK HK01107165A patent/HK1037877A1/xx not_active IP Right Cessation
2002
- 2002-06-18 US US10/174,380 patent/US20020193406A1/en not_active Abandoned

Also Published As

Publication number	Publication date
GB9909505D0 (en)	1999-06-23
DE69911774D1 (de)	2003-11-06
AR011759A1 (es)	2000-09-13
DE60000003T2 (de)	2002-03-21
BR9911682A (pt)	2001-12-26
GR3034328T3 (en)	2000-12-29
GB9920332D0 (en)	1999-11-03
US20010023253A1 (en)	2001-09-20
GB0026487D0 (en)	2000-12-13
SI0970955T1 (en)	2001-02-28
IL140628A0 (en)	2002-02-10
SE9901462L (fi)
DK199900554A (da)	2000-01-03
NL1012272C1 (nl)	1999-07-12
CA2269999A1 (en)	2000-01-02
EP1020464A1 (en)	2000-07-19
GR990100140A (el)	2000-03-31
GB2352395B (en)	2004-02-11
NO991944L (no)	2000-01-03
PT970955E (pt)	2000-11-30
ATE251155T1 (de)	2003-10-15
IES20000894A2 (en)	2001-05-30
SE9901462A0 (sv)	2000-01-03
SI1020464T1 (en)	2001-12-31
ES2157881T3 (es)	2001-09-01
CN1315949A (zh)	2001-10-03
PT102291A (pt)	2000-05-31
FI990922A (fi)	2000-01-03
DE29907248U1 (de)	1999-09-09
GB0119695D0 (en)	2001-10-03
GB0216752D0 (en)	2002-08-28
US6063927A (en)	2000-05-16
IL140628A (en)	2004-06-20
ES2149044T3 (es)	2000-10-16
KR20010053336A (ko)	2001-06-25
FR2780728A1 (fr)	2000-01-07
AU2392899A (en)	2000-01-20
DK1089996T3 (da)	2004-02-09
LU90388B1 (fr)	2001-01-29
NL1011875A1 (nl)	2000-01-07
IE20000633A1 (en)	2001-10-17
DK199900234U4 (da)	2000-12-22
GB2367003A (en)	2002-03-27
NL1012271A1 (nl)	1999-07-12
PT1089996E (pt)	2004-02-27
EP1089996A1 (en)	2001-04-11
DE19918588A1 (de)	2000-01-27
IES20000893A2 (en)	2001-05-30
HK1037877A1 (en)	2002-02-22
HUP0102334A2 (hu)	2002-05-29
AU713877B3 (en)	1999-12-09
EP1020464B1 (en)	2001-07-04
FI112077B (fi)	2003-10-31
ITMI990866A1 (it)	2000-10-23
IES81166B2 (en)	2000-05-31
PT1020464E (pt)	2001-10-30
ES2158778B1 (es)	2002-03-16
GB2336364A (en)	1999-10-20
FI990922A0 (fi)	1999-04-23
GB2377637A (en)	2003-01-22
SK20262000A3 (sk)	2001-07-10
FR2802098A1 (fr)	2001-06-15
NL1012271C2 (nl)	1999-09-23
ATE202777T1 (de)	2001-07-15
AU3619199A (en)	2000-01-24
GR3036208T3 (en)	2001-10-31
DK199900234U1 (da)	2000-12-22
TR200100054T2 (tr)	2001-06-21
CH689805A8 (fr)	2000-02-29
DK199900176U3 (da)	1999-08-13
IES990343A2 (en)	2000-01-02
SE9901462D0 (sv)	1999-04-23
EP1288214A1 (en)	2003-03-05
AU732211C (en)	2004-05-06
NL1011874C1 (nl)	1999-07-12
ES2158778A1 (es)	2001-09-01
BE1012420A6 (fr)	2000-10-03
GB2336364B (en)	2000-05-10
DK1020464T3 (da)	2001-09-24
JP2002519422A (ja)	2002-07-02
DK200000390U1 (da)	2000-12-27
AU713131B3 (en)	1999-11-25
EP0970955B1 (en)	2000-08-02
DE60000003D1 (de)	2001-08-09
DE69900007T2 (de)	2001-06-07
FI4209U1 (fi)	1999-11-10
BE1011664A6 (fr)	1999-11-09
EP1020463A1 (en)	2000-07-19
AR018197A1 (es)	2001-10-31
EP1089996B1 (en)	2003-10-01
ES2209428T3 (es)	2004-06-16
US20020035130A1 (en)	2002-03-21
IE990344A1 (en)	2000-05-03
NO991944D0 (no)	1999-04-23
AU732211B2 (en)	2001-04-12
DE69911774T2 (de)	2004-08-05
FIU990190U0 (fi)	1999-04-23
NZ509180A (en)	2001-06-29
BE1012403A5 (fr)	2000-10-03
AT3185U3 (de)	2000-01-25
CN1127502C (zh)	2003-11-12
GB2352395A (en)	2001-01-31
IT1312540B1 (it)	2002-04-22
EP0970955A1 (en)	2000-01-12
WO2000001694A1 (en)	2000-01-13
US20020193406A1 (en)	2002-12-19
NL1011875C2 (nl)	2000-03-24
AT3185U2 (de)	1999-11-25
CH689805A5 (fr)	1999-11-30
SI1089996T1 (en)	2004-04-30
FR2780728B1 (fr)	2001-02-16
PL345214A1 (en)	2001-12-03
GR1003350B (el)	2000-03-29
ATE195121T1 (de)	2000-08-15
DE69900007D1 (de)	2000-09-07
PT102291B (pt)	2002-07-31
GB2339428A (en)	2000-01-26
HUP0102334A3 (en)	2003-12-29
DK0970955T3 (da)	2000-10-09

Publication	Publication Date	Title
NO319030B1 (no)	2005-06-06	Paroxetinmetansulfonat, anvendelse derav samt fremgangsmate for fremstilling og farmasoytisk preparat.
AU2002100370A4 (en)	2002-06-06	Novel compound
AU724845B3 (en)	2000-09-28	Novel compound
AU2001100025A4 (en)	2001-06-21	Novel compound
AU732558B3 (en)	2001-04-26	Novel compound
MXPA01000307A (en)	2001-09-07	Paroxetine methanesulfonate
AU5430701A (en)	2001-12-06	Novel compound
CZ20004924A3 (cs)	2001-06-13	Methansulfonat paroxetinu